Patents by Inventor Francis Burrows

Francis Burrows has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11944627
    Abstract: The present disclosure provides methods for treating hematological malignancies and Ewings sarcoma using menin inhibitors. Compositions for use in these methods are also provided.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: April 2, 2024
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Francis Burrows, Linda V. Kessler, Liansheng Li, Pingda Ren, Yi Wang, Tao Wu, Jingchuan Zhang
  • Publication number: 20240024301
    Abstract: Provided herein are methods of tipifarnib in combination with a PI3K inhibitor, such as alpelisib, for treating, preventing or managing head and neck squamous cell carcinoma (HNSCC).
    Type: Application
    Filed: July 20, 2023
    Publication date: January 25, 2024
    Inventors: Francis Burrows, Mollie Leoni, Shivani Malik, Vishnu S. Mishra, Alison Smith, Harris Soifer
  • Publication number: 20230405008
    Abstract: The present disclosure provides methods for treating hematological malignancies using menin inhibitors. Compositions for use in these methods are also provided.
    Type: Application
    Filed: October 19, 2021
    Publication date: December 21, 2023
    Inventors: Francis BURROWS, Blake TOMKINSON
  • Publication number: 20230248683
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating Squamous Cell Carcinoma in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the expression level of H-Ras.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 10, 2023
    Inventors: Francis Burrows, Yi Liu
  • Patent number: 11672774
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating Squamous Cell Carcinoma in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the expression level of H-Ras.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: June 13, 2023
    Assignee: Kura Oncology, Inc.
    Inventors: Francis Burrows, Yi Liu
  • Publication number: 20230095934
    Abstract: The present disclosure provides methods for treating hematological malignancies using menin inhibitors. Compositions for use in these methods are also provided.
    Type: Application
    Filed: September 26, 2019
    Publication date: March 30, 2023
    Inventor: Francis BURROWS
  • Publication number: 20230026872
    Abstract: The present disclosure provides methods for treating hematological malignancies and Ewings sarcoma using menin inhibitors. Compositions for use in these methods are also provided.
    Type: Application
    Filed: March 22, 2018
    Publication date: January 26, 2023
    Inventors: Francis BURROWS, Linda V. KESSLER, Liansheng LI, Pingda REN, Yi WANG, Tao WU, Jingchuan ZHANG, I
  • Publication number: 20220117927
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating Squamous Cell Carcinoma in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the expression level of H-Ras.
    Type: Application
    Filed: September 28, 2021
    Publication date: April 21, 2022
    Inventors: Francis Burrows, Yi Liu
  • Publication number: 20190192517
    Abstract: The present disclosure provides methods and systems for identifying and/or treating subjects having cancer, such as squamous cell carcinoma, who are more likely to respond to treatment with an ERK inhibitor.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 27, 2019
    Inventors: Francis Burrows, Dana Hu-Lowe, Linda Kessler
  • Publication number: 20080051462
    Abstract: The invention relates generally to methods of treating cell proliferative diseases with HSP90 inhibitors and, depending on the specific aspect and embodiment(s) claimed, to the treatment of proliferative diseases that are associated with fusion proteins, e.g., berab1, or mutant proteins or cellular protein isoforms, e.g., mutant forms of p53.
    Type: Application
    Filed: July 17, 2007
    Publication date: February 28, 2008
    Inventors: Lawrence Fritz, Francis Burrows
  • Publication number: 20070105874
    Abstract: The present invention provides a method of treating an individual having an HSP90 mediated disorder comprising administering to said individual a pharmaceutical composition comprising a pharmaceutically effective amount of a synthetic heterocyclic HSP90 inhibitor, wherein the activity of the HSP90 inhibitor is substantially independent of multi drug resistance. In one embodiment, the activity of the HSP90 inhibitor is substantially independent of P-gp and MRP expression.
    Type: Application
    Filed: September 25, 2006
    Publication date: May 10, 2007
    Applicant: Conforma Therapeutics Corporation
    Inventors: Hong Zhang, Francis Burrows
  • Publication number: 20060251574
    Abstract: Cytotoxic compounds and diagnostic imaging agents comprising HSP90-ligands and methods of use thereof are described.
    Type: Application
    Filed: June 12, 2003
    Publication date: November 9, 2006
    Inventors: Adeela Kamal, Francis Burrows, Lin Zhang, Marcus Boehm
  • Publication number: 20060210473
    Abstract: The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.
    Type: Application
    Filed: February 28, 2006
    Publication date: September 21, 2006
    Inventors: Philip Thorpe, Francis Burrows
  • Publication number: 20060079493
    Abstract: The invention relates generally to methods of treating cell proliferative diseases with HSP90 inhibitors and, depending on the specific aspect and embodiment(s) claimed, to the treatment of proliferative diseases that are associated with fusion proteins, e.g., bcrabl, or mutant proteins or cellular protein isoforms, e.g., mutant forms of p53.
    Type: Application
    Filed: March 1, 2002
    Publication date: April 13, 2006
    Inventors: Lawrence Fritz, Francis Burrows
  • Publication number: 20050267122
    Abstract: Ansamycins and methods of preparing and using the same are described. At least some of these ansamycins exhibit one or more of improved aqueous formulation ability, chemical stability, and bioavailability. Some of the derivatives described are dimers. These and others described can include one or more solubilizing groups that have expected merit in rendering the overall compounds useful as drugs and prodrugs.
    Type: Application
    Filed: February 10, 2003
    Publication date: December 1, 2005
    Inventors: Lin Zhang, Jean-Yves Le Brazidec, Lawrence Fritz, Francis Burrows, Marcus Boehm, Junhua Fan, Sean McHugh
  • Publication number: 20050074457
    Abstract: Ligand binding assays as applied to HSP90s as receptors or ligands, and reagents useful therefore, are described and claimed, as are methods of assaying for HSP90 modulators and methods of using the resulting products identified thereby.
    Type: Application
    Filed: December 12, 2002
    Publication date: April 7, 2005
    Inventors: Adeela Kamal, Francis Burrows, Lin Zhang, Marcus Boehm